Second-line treatment of metastatic gastric cancer in the era of predictive biomarkers: A cost-effectiveness analysis.

e15517Background: Gastric cancer is the third leading cause of cancer-related mortality, with only a 30% five-year survival rate. Patients who progress after one round of systemic therapy face an e...